KROS - Keros Therapeutics Inc

11.27
-0.310   -2.751%

Share volume: 625,841
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$11.58
-0.31
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
44%
Profitability 43%
Dept financing 19%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-0.70%
1 Month
-32.15%
3 Months
-47.61%
6 Months
-28.03%
1 Year
-4.17%
2 Year
-83.32%
Key data
Stock price
$11.27
P/E Ratio 
N/A
DAY RANGE
$11.07 - $11.53
EPS 
$1.97
52 WEEK RANGE
$9.12 - $22.55
52 WEEK CHANGE
-$1.74
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
19.718 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
0.91
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$562,913
AVERAGE 30 VOLUME 
$410,273
Company detail
CEO: Jasbir S. Seehra
Region: US
Website: kerostx.com
Employees: 100
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Keros Therapeutics, Inc. focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia.

Recent news